著作: Watanabe Miho/Tajima Soichiro/[片島 るみ]/Miyamoto Toshiko/Yamagami Makiko/[水口 和生]/[楊河 宏章]/Serious adverse events and compensation in registration trials: a review of data from a Japanese university hospital./[BMC Research Notes]
ヘルプを読む
「著作」(著作(著書,論文,レター,国際会議など))は,研究業績にかかる著作(著書,論文,レター,国際会議など)を登録するテーブルです. (この情報が属するテーブルの詳細な定義を見る)
- 項目名の部分にマウスカーソルを置いて少し待つと,項目の簡単な説明がツールチップ表示されます.
種別 | 必須 | 学術論文(審査論文) | |||
---|---|---|---|---|---|
言語 | 必須 | 英語 | |||
招待 | 推奨 | ||||
審査 | 推奨 | ||||
カテゴリ | 推奨 | ||||
共著種別 | 推奨 | ||||
学究種別 | 推奨 | ||||
組織 | 推奨 | ||||
著者 | 必須 | ||||
題名 | 必須 |
(英) Serious adverse events and compensation in registration trials: a review of data from a Japanese university hospital. |
|||
副題 | 任意 | ||||
要約 | 任意 |
(英) Clinical trials leading to regulatory approval, or registration trials, play a central role in the development of drugs and medical devices. The contribution of support staff, such as the clinical research coordinator (CRC) and administrative officers, in registration trials is now widely recognized. Attending to serious adverse events is an important duty of the CRC and investigators alike, and managing these complications and compensation constitutes a key responsibility. We retrospectively examined the frequency of serious adverse events and compensation events reported from 2007 through 2011 at Tokushima University Hospital, an academic hospital in rural Japan. We present herein the results of our analysis. Over the five-year period, 284 subjects participating in 106 registration trials experienced a total of 43 serious adverse events, and eight compensation events were documented. Among the serious adverse events, 35 (81.4%) were considered not related to the investigational drug, and 17 (39.5%) resulted in withdrawal of the study drug. Patients with malignant diseases experienced serious adverse events significantly more frequently compared to those with non-malignant diseases (28.3% versus 8.2%, respectively; P < 0.01). The CRC should be vigilant for serious adverse events in oncology clinical trials due to the generally higher frequency of these complications in subjects with malignancy. However, on an individual basis, the CRC may be seldom involved in the process for compensating serious adverse events. Therefore, the CRC's ability to share such experiences may serve as an opportunity for educating clinical trial support staff at the study site as well as those at other sites. However, further study is warranted to determine the role of the clinical trial support staff in optimizing methods for managing adverse events requiring compensation in registration trials. |
|||
キーワード | 推奨 | ||||
発行所 | 推奨 | ||||
誌名 | 必須 |
BMC Research Notes([BioMed Central Ltd.])
(eISSN: 1756-0500)
|
|||
巻 | 必須 | 7 | |||
号 | 必須 | ||||
頁 | 必須 | 245 245 | |||
都市 | 任意 | ||||
年月日 | 必須 | 2014年 4月 17日 | |||
URL | 任意 | ||||
DOI | 任意 | 10.1186/1756-0500-7-245 (→Scopusで検索) | |||
PMID | 任意 | 24742228 (→Scopusで検索) | |||
CRID | 任意 | ||||
WOS | 任意 | ||||
Scopus | 任意 | ||||
評価値 | 任意 | ||||
被引用数 | 任意 | ||||
指導教員 | 推奨 | ||||
備考 | 任意 |
|